Autolus Therapeutics plc (NASDAQ:AUTL) Shares Sold by Fred Alger Management LLC

Fred Alger Management LLC trimmed its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 99.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,262 shares of the company’s stock after selling 1,186,614 shares during the period. Fred Alger Management LLC’s holdings in Autolus Therapeutics were worth $36,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AUTL. ProShare Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 2nd quarter worth about $43,000. Daiwa Securities Group Inc. raised its position in shares of Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after buying an additional 15,293 shares in the last quarter. Bayesian Capital Management LP bought a new stake in shares of Autolus Therapeutics during the 1st quarter worth about $100,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Autolus Therapeutics during the 1st quarter worth about $108,000. Finally, SG Americas Securities LLC bought a new stake in shares of Autolus Therapeutics during the 1st quarter worth about $127,000. 72.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on the stock. Needham & Company LLC restated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday, June 17th. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.70.

Autolus Therapeutics Stock Up 4.3 %

NASDAQ AUTL opened at $3.63 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. The company’s 50 day simple moving average is $4.00 and its 200 day simple moving average is $4.33. Autolus Therapeutics plc has a 12 month low of $2.01 and a 12 month high of $7.45. The company has a market capitalization of $965.71 million, a P/E ratio of -3.03 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). Equities research analysts expect that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.